CLOs on the Move

ColoWrap

www.colowrap.com

 
ColoWrap is the first clinical colonoscopy compression device that prevents the need for manual abdominal pressure and patient repositioning during colonoscopy.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.colowrap.com
  • 413, W Cornwallis Rd
    Durham, NC USA 27707
  • Phone: 919.451.1803

Executives

Name Title Contact Details

Similar Companies

Innovative Seating

Innovative Seating Solutions manufactures custom-fitted chairs, back orthotics and seat cushions to relieve pain and enhance seating comfort.

Novo Nordisk Canada

Novo Nordisk Canada Inc. is an affiliate of Novo Nordisk A/S, a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,400 employees in 77 countries, and markets its products in more than 165 countries.

Immune Pharmaceuticals

Immune Pharmaceuticals is developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases.

Sanofi

3129 Sanofi SA is a French multinational healthcare company headquartered in Paris, France.

Radionetics

Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company`s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.